文献速递生殖医学产科

复发性流产女性IVF冻胚移植中PGT-A与非PGT-A的妊娠结局:SART-CORS研究

Pregnancy outcomes following in vitro fertilization frozen embryo transfer (IVF-FET) with or without preimplantation genetic testing for aneuploidy (PGT-A) in women with recurrent pregnancy loss (RPL): a SART-CORS study.
PubMed 文献 · Hum Reprod · 2021-01-01

结果显示PGT-A与活产率改善相关,且年龄越大获益越明显,>42岁组调整OR达3.80(95%CI 2.52,5.72)。

要点

  • RPL女性冻胚移植中,PGT-A与活产率改善相关,年龄越大获益越显著。
  • 各年龄层活产调整OR均>1,最高为>42岁组3.80(95%CI 2.52,5.72)。
  • 临床妊娠率同样改善,但自然流产率各年龄层OR均无统计学显著差异。

核心结论

  • 在复发性流产(RPL)女性行冻胚移植(IVF-FET)时,使用PGT-A与活产率改善相关。
  • 年龄越大,PGT-A与活产率改善的关联越强,>42岁组调整OR为3.80(95%CI 2.52,5.72)。
  • PGT-A与临床妊娠率改善相关,但自然流产率的OR在各年龄层均无统计学显著差异。

研究设计与样本

  • 回顾性队列研究,数据来自SART-CORS 2010至2016年IVF-FET周期。
  • 实验组为RPL(严格定义为≥3次妊娠丢失)行FET伴或不伴PGT-A的夫妇。
  • 采用广义估计方程逻辑回归模型分析,校正年龄、孕次、地区、种族、吸烟史及辅助生殖指征。
  • 按SART年龄分组(<35、35-37、38-40、41-42、>42岁)进行分层分析。

主要发现

  • 活产调整OR:<35岁1.31(95%CI 1.12,1.52);35-37岁1.45(95%CI 1.21,1.75);38-40岁1.89(95%CI 1.56,2.29);41-42岁2.62(95%CI 1.94,3.53);>42岁3.80(95%CI 2.52,5.72)。
  • 临床妊娠OR:<35岁1.26(95%CI 1.08,1.48);35-37岁1.37(95%CI 1.14,1.64);38-40岁1.68(95%CI 1.40,2.03);41-42岁2.19(95%CI 1.65,2.90);>42岁2.31(95%CI 1.60,3.32)。
  • 自然流产OR:<35岁0.95(95%CI 0.74,1.21);35-37岁0.85(95%CI 0.65,1.11);38-40岁0.81(95%CI 0.60,1.08);41-42岁0.86(95%CI 0.58,1.27);>42岁0.58(95%CI 0.32,1.07)。

关键数值与推荐

  • RPL严格定义为有3次或以上妊娠丢失史。
  • 主要结局为活产率,次要结局包括临床妊娠率、自然流产率和生化妊娠丢失率。
  • 年龄分层依据SART标准:<35、35-37、38-40、41-42、>42岁。

临床怎么用

  • 对RPL夫妇进行咨询时应告知所有降低后续流产的管理选择,可包括IVF联合PGT-A选择整倍体胚胎。
  • 年龄>42岁的RPL女性行FET时,PGT-A与活产率改善的关联最强,可优先考虑。
  • 临床决策需结合患者年龄及个体情况,权衡PGT-A的潜在获益。

局限性

  • 回顾性数据收集,仅纳入行FET的RPL女性,结果可能无法推广至所有RPL夫妇。
  • 缺乏纳入女性的RPL评估和治疗相关数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can preimplantation genetic testing for aneuploidy (PGT-A) improve the live birth rate in patients with recurrent pregnancy loss (RPL)? SUMMARY ANSWER: PGT-A use was associated with improved live birth rates in couples with recurrent pregnancy loss undergoing frozen embryo transfer (IVF-FET). WHAT IS KNOWN ALREADY: Euploid embryo transfer is thought to optimize outcomes in some couples with infertility. There is insufficient evidence, however, supporting this approach to management of recurrent pregnancy loss. STUDY DESIGN, SIZE, DURATION: This study included data collected by the Society of Assisted Reproductive Technologies Clinical Outcomes Reporting System (SART-CORS) for IVF-FET cycles between years 2010 through 2016. A total of 12 631 FET cycles in 10 060 couples were included in this analysis designed to assess the utility of PGT-A in couples with RPL undergoing FET, including 4287 cycles in couples with tubal disease who formed a control group. PARTICIPANTS/MATERIALS, SETTING, METHODS: The experimental group included couples with RPL (strictly defined as a history of 3 or more pregnancy losses) undergoing FET with or without PGT-A. The primary outcome was live birth rate. Secondary outcomes included rates of clinical pregnancy, spontaneous abortion, and biochemical pregnancy loss. Differences were analyzed using generalized estimating equations logistic regression models to account for multiple cycles per patient. Covariates included in the model were age, gravidity, geographic region, race/ethnicity, smoking history, and indication for assisted reproductive technologies. Analyses were stratified for age groups as defined by SART: <35 years, 35-37 years, 38-40 years, 41-42 years, and >42 years. MAIN RESULTS AND THE ROLE OF CHANCE: In women with a diagnosis of RPL, the adjusted odds ratio (OR) comparing IVF-FET with PGT-A versus without PGT-A for live birth outcome was 1.31 (95% CI: 1.12, 1.52) for age <35 years, 1.45 (95% CI: 1.21, 1.75) for ages 35-37 years, 1.89 (95% CI: 1.56, 2.29) for ages 38-40, 2.62 (95% CI: 1.94-3.53) for ages 41-42, and 3.80 (95% CI: 2.52, 5.72) for ages >42 years. For clinical pregnancy, the OR was 1.26 (95% CI: 1.08, 1.48) for age <35 years, 1.37 (95% CI: 1.14, 1.64) for ages 35-37 years, 1.68 (95% CI: 1.40, 2.03) for ages 38-40 years, 2.19 (95% CI: 1.65, 2.90) for ages 41-42, and 2.31 (95% CI: 1.60, 3.32) for ages >42 years. Finally, for spontaneous abortion, the OR was 0.95 (95% CI: 0.74, 1.21) for age <35 years, 0.85 (95% CI: 0.65, 1.11) for ages 35-37 years, 0.81 (95% CI: 0.60, 1.08) for ages 38-40, 0.86 (95% CI: 0.58, 1.27) for ages 41-42, and 0.58 (95% CI: 0.32, 1.07) for ages >42 years. LIMITATIONS, REASONS FOR CAUTION: The retrospective collection of data including only women with recurrent pregnancy loss undergoing FET presents a limitation of this study, and results may not be generalizable to all couples with recurrent pregnancy loss. Also, data regarding evaluation and treatment for RPL for the included women is unavailable. WIDER IMPLICATIONS OF THE FINDINGS: This is the largest study to date assessing the utility of PGT-A in women with RPL. PGT-A was associated with improvement in live birth and clinical pregnancy in women with RPL, with the largest difference noted in the group of women with age greater than 42 years. Couples with RPL warrant counseling on all management options to reduce subsequent miscarriage, which may include IVF with PGT-A for euploid embryo selection. STUDY FUNDING/COMPETING INTEREST(S): There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Bhatt SJ, Marchetto NM, Roy J, et al. Pregnancy outcomes following in vitro fertilization frozen embryo transfer (IVF-FET) with or without preimplantation genetic testing for aneuploidy (PGT-A) in women with recurrent pregnancy loss (RPL): a SART-CORS study. Hum Reprod. 2021. PMID: 34027546. doi:10.1093/humrep/deab117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。